Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADTXNASDAQ:ENVBNASDAQ:REVBNASDAQ:VRAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADTXAditxt$1.38-4.8%$1.99$1.34▼$27,200.00$2.93M1.49799,974 shs79,514 shsENVBEnveric Biosciences$1.21-2.4%$1.26$1.01▼$11.55$2.99M0.53773,056 shs100,804 shsREVBRevelation Biosciences$0.79-1.4%$2.45$0.77▼$60.80$765K-0.09362,557 shs308,476 shsVRAXVirax Biolabs Group$0.88-8.1%$1.01$0.82▼$9.00$2.85M1.771.74 million shs73,967 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADTXAditxt-4.83%-10.39%-16.87%+6,765.67%-99.99%ENVBEnveric Biosciences-2.42%-6.92%-7.63%-30.06%-89.40%REVBRevelation Biosciences-1.37%-7.61%-74.63%-76.65%-97.80%VRAXVirax Biolabs Group-8.07%-9.81%-18.66%-35.58%-47.47%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADTXAditxt0.9973 of 5 stars0.05.00.00.02.50.00.6ENVBEnveric Biosciences2.0396 of 5 stars3.52.00.00.01.80.01.3REVBRevelation Biosciences0.4332 of 5 stars0.02.00.00.01.90.01.3VRAXVirax Biolabs Group3.3384 of 5 stars3.55.00.00.03.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADTXAditxt 0.00N/AN/AN/AENVBEnveric Biosciences 3.00Buy$10.00726.45% UpsideREVBRevelation Biosciences 0.00N/AN/AN/AVRAXVirax Biolabs Group 3.00Buy$3.00239.94% UpsideCurrent Analyst Ratings BreakdownLatest REVB, VRAX, ENVB, and ADTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2025VRAXVirax Biolabs GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADTXAditxt$55.32K52.88N/AN/A$2,687.49 per share0.00ENVBEnveric BiosciencesN/AN/AN/AN/A$10.71 per shareN/AREVBRevelation BiosciencesN/AN/AN/AN/A$402.10 per shareN/AVRAXVirax Biolabs Group$84.87K33.62N/AN/A$2.00 per share0.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADTXAditxt-$32.38MN/A0.00∞N/AN/A-439.07%-122.96%8/18/2025 (Estimated)ENVBEnveric Biosciences-$17.29M-$38.38N/AN/AN/AN/A-221.54%-164.32%8/11/2025 (Estimated)REVBRevelation Biosciences-$120K-$102.61N/AN/AN/AN/A-193.51%-84.00%8/8/2025 (Estimated)VRAXVirax Biolabs Group-$6.73MN/A0.00∞N/AN/AN/AN/AN/ALatest REVB, VRAX, ENVB, and ADTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ADTXAditxt-$26,400.00-$8.12+$26,391.88-$8.12$0.43 million$0.00 million5/14/2025Q1 2025ENVBEnveric Biosciences-$3.45-$1.22+$2.23-$1.22N/AN/A5/8/2025Q1 2025REVBRevelation Biosciences-$6.88-$2.11+$4.77-$2.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADTXAditxtN/AN/AN/AN/AN/AENVBEnveric BiosciencesN/AN/AN/AN/AN/AREVBRevelation BiosciencesN/AN/AN/AN/AN/AVRAXVirax Biolabs GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADTXAditxtN/A0.090.08ENVBEnveric BiosciencesN/A5.175.17REVBRevelation BiosciencesN/A1.641.64VRAXVirax Biolabs GroupN/A11.5711.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADTXAditxt15.54%ENVBEnveric Biosciences13.82%REVBRevelation Biosciences12.80%VRAXVirax Biolabs Group8.61%Insider OwnershipCompanyInsider OwnershipADTXAditxt0.01%ENVBEnveric Biosciences1.10%REVBRevelation Biosciences0.06%VRAXVirax Biolabs Group45.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADTXAditxt602.12 million14.23 millionNo DataENVBEnveric Biosciences202.47 million656,000Not OptionableREVBRevelation Biosciences10964,000268,000Not OptionableVRAXVirax Biolabs Group53.23 million1.78 millionNot OptionableREVB, VRAX, ENVB, and ADTX HeadlinesRecent News About These CompaniesHC Wainwright & Co. Initiates Coverage of Virax Biolabs Group (VRAX) with Buy RecommendationMarch 31, 2025 | msn.comVirax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy RatingMarch 31, 2025 | benzinga.comVirax Biolabs Launches Clinical Study on T Cell DysfunctionMarch 18, 2025 | msn.comVirax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection SyndromesMarch 18, 2025 | prnewswire.comVirax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation MeetingMarch 13, 2025 | prnewswire.comVirax Biolabs to Present at 19th World Immune Regulation MeetingMarch 5, 2025 | prnewswire.comVirax Biolabs Aligns with US Health Department on Vaccine TransparencyFebruary 25, 2025 | tipranks.comVirax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine EfficacyFebruary 25, 2025 | prnewswire.comCosmos Health expands distribution of Avian Influenza kitsJanuary 23, 2025 | msn.comCosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and KuwaitJanuary 23, 2025 | accessnewswire.comCosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC CountriesJanuary 13, 2025 | accesswire.comVirax Biolabs Group Ltd (VRAX) Stock: Beyond the Surface of Its Performance?December 19, 2024 | bovnews.comVirax Biolabs Announces Strategic Goals and Developments for 2025December 18, 2024 | markets.businessinsider.comVirax Biolabs' CEO James Foster Issues Letter to ShareholdersDecember 17, 2024 | prnewswire.comVirax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and SwitzerlandDecember 10, 2024 | prnewswire.comVirax Biolabs Sees Asset Growth Amid Financial LossNovember 22, 2024 | markets.businessinsider.comVirax Biolabs announces distribution agreement with Europa BiositeOctober 24, 2024 | markets.businessinsider.comVirax Biolabs Expands Reach with Europa Biosite DealOctober 24, 2024 | markets.businessinsider.comVirax Biolabs Signs Distribution Agreement With Europa Biosite To Sell ImmuneSelect; Stock UpOctober 23, 2024 | markets.businessinsider.comVirax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and IrelandOctober 23, 2024 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeREVB, VRAX, ENVB, and ADTX Company DescriptionsAditxt NASDAQ:ADTX$1.38 -0.07 (-4.83%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.42 +0.04 (+2.61%) As of 06/13/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.Enveric Biosciences NASDAQ:ENVB$1.21 -0.03 (-2.42%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$1.23 +0.02 (+1.65%) As of 06/13/2025 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.Revelation Biosciences NASDAQ:REVB$0.79 -0.01 (-1.37%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.79 -0.01 (-0.63%) As of 06/13/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.Virax Biolabs Group NASDAQ:VRAX$0.88 -0.08 (-8.07%) Closing price 06/13/2025 03:48 PM EasternExtended Trading$0.97 +0.09 (+9.92%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
